Marker Therapeutics’ (MRKR) “Strong-Buy” Rating Reiterated at WBB Securities

Marker Therapeutics (NASDAQ:MRKR)‘s stock had its “strong-buy” rating reaffirmed by analysts at WBB Securities in a research note issued on Tuesday,Benzinga reports. They presently have a $12.50 target price on the stock.

Several other analysts have also weighed in on MRKR. Brookline Capital Management raised Marker Therapeutics to a “strong-buy” rating in a report on Monday, February 10th. Canaccord Genuity Group assumed coverage on shares of Marker Therapeutics in a research note on Wednesday, March 5th. They set a “buy” rating and a $8.00 price target on the stock.

Marker Therapeutics Trading Down 3.1 %

NASDAQ MRKR opened at $1.23 on Tuesday. Marker Therapeutics has a twelve month low of $1.13 and a twelve month high of $5.99. The firm has a 50-day simple moving average of $1.60 and a 200 day simple moving average of $2.72.

Institutional Investors Weigh In On Marker Therapeutics

Large investors have recently modified their holdings of the stock. Alyeska Investment Group L.P. acquired a new position in Marker Therapeutics during the fourth quarter worth $2,847,000. NEA Management Company LLC grew its holdings in shares of Marker Therapeutics by 51.7% in the 4th quarter. NEA Management Company LLC now owns 1,625,678 shares of the company’s stock worth $5,056,000 after purchasing an additional 554,250 shares during the last quarter. Blue Owl Capital Holdings LP acquired a new stake in shares of Marker Therapeutics during the 4th quarter worth about $1,724,000. LPL Financial LLC bought a new position in Marker Therapeutics during the 4th quarter valued at about $248,000. Finally, Northern Trust Corp boosted its position in Marker Therapeutics by 66.9% in the fourth quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock valued at $168,000 after buying an additional 21,703 shares in the last quarter. 22.39% of the stock is currently owned by institutional investors.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.